A series
of indolyl-3-methyleneamines incorporating lipophilic
side chains were designed through a structural rigidification approach
and synthesized for investigation as new chemical entities against Mycobacterium tuberculosis (Mtb). The screening led to the
identification of a 6-chloroindole analogue 7j bearing
an N-octyl chain and a cycloheptyl moiety, which
displayed potent in vitro activity against laboratory
and clinical Mtb strains, including a pre-extensively drug-resistant
(pre-XDR) isolate. 7j also demonstrated a marked ability
to restrict the intracellular growth of Mtb in murine macrophages.
Further assays geared toward mechanism of action elucidation have
thus far ruled out the involvement of various known promiscuous targets,
thereby suggesting that the new indole 7j may inhibit
Mtb via a unique mechanism.